padeliporfin
Trade name: Tookad
Small moleculeexperimental
Padeliporfin, sold under the brand name Tookad, is a medication used to treat men with prostate cancer. It is used in the form padeliporfin di-potassium. — Wikipedia
Clinical trial activity
11 trials · 13 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
7
Phase 3
5
Phase 4
1
Earliest trial started Apr 1, 2004 (NCT00308919)
Timeline
Indications
Approved for
Mechanism of action
- Unspecified targetOTHER
Unknown
Vascular targeted photodynamic therapy. The compound becomes pharmaceutically active when illuminated by light to generate free radicals and other reactive species.
Chemistry & pharmacology
- Mol. weight
- 840.26 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPadeliporfin ↗
- ChEMBLCHEMBL4594284 ↗
Also known as
- padeliporfin di-potassium
- palladium-bacteriopheophorbide
- pd-bacteriopheophorbide
- pd-bpheid
- tookad
- tookad
- tookad
- wst09
- wst09
- wst 09
- wst-09
- wst09 cpd
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05919238 | Phase 1 | Oct 30, 2023 | Impact Therapeutics, Inc. |
| NCT05918783 | Phase 1 | Oct 30, 2023 | Impact Therapeutics, Inc. |
| NCT04620239 | Phase 3 | Jan 11, 2021 | ICON, Medpace, Inc., Memorial Sloan-Kettering Cancer Center, PrimeVigilance LTD, Steba Biotech S.A. |
| NCT04225299 | Phase 3 | Jan 31, 2020 | Memorial Sloan-Kettering Cancer Center, Steba Biotech S.A. |
| NCT03849365 | Phase 4 | Jan 21, 2019 | International Drug Development Institute, PrimeVigilance LTD, Steba Biotech S.A., University of Angers |
| NCT03315754 | Phase 2 | Oct 2, 2017 | Memorial Sloan-Kettering Cancer Center, Steba Biotech S.A. |
| NCT01875393 | Phase 3 | May 1, 2013 | Cayetano Heredia University, Hospital General Tlahuac, Pan-American Medical Research Institute, Steba Biotech S.A. |
| NCT01310894 | Phase 3 | Feb 1, 2011 | Steba Biotech S.A., University of London |
| NCT00312442 | Phase 2/Phase 3 (Phase 3) | May 1, 2006 | Steba Biotech S.A., University of Toronto |
| NCT00305929 | Phase 2 | Mar 1, 2006 | Steba Biotech S.A., University of Toronto |
| NCT00308919 | Phase 2 | Apr 1, 2004 | Steba Biotech S.A., University of Toronto |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Steba Biotech S.A. | For profit | 9 | 9 | 3 | 2004 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 3 | 0 | 2 | 2017 |
| University of Toronto | Academic/Hospital | 3 | 0 | 2 | 2004 |
| Impact Therapeutics, Inc. | For profit | 2 | 2 | 1 | 2023 |
| PrimeVigilance LTD | For profit | 2 | 0 | 2 | 2019 |
| Cayetano Heredia University | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Hospital General Tlahuac | Academic/Hospital | 1 | 0 | 1 | 2013 |
| ICON | For profit | 1 | 0 | 1 | 2021 |
| International Drug Development Institute | For profit | 1 | 0 | 1 | 2019 |
| Medpace, Inc. | For profit | 1 | 0 | 1 | 2021 |
| Pan-American Medical Research Institute | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of Angers | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2011 |
13 organizations
Page 1 / 1